TG Therapeutics Company Insiders
| TGTX Stock | USD 33.36 0.01 0.03% |
TG Therapeutics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding TG Therapeutics suggests that vertually all insiders are panicking. TG Therapeutics employs about 319 people. The company is managed by 5 executives with a total tenure of roughly 15 years, averaging almost 3.0 years of service per executive, having 63.8 employees per reported executive.
| Adam Waldman Executive Chief Commercial Officer |
TG Therapeutics' Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
| 2025-01-06 | Sean A Power | Disposed 10021 @ 28.53 | View | ||
| 2025-01-03 | Sean A Power | Disposed 11337 @ 30.29 | View | ||
| 2024-11-11 | Sagar Lonial | Disposed 5000 @ 30.44 | View | ||
| 2024-03-12 | Laurence N Charney | Disposed 22000 @ 15.97 | View |
Monitoring TG Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
TGTX |
TG Therapeutics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with TG Therapeutics' future performance. Based on our forecasts, it is anticipated that TGTX will maintain a workforce of slightly above 320 employees by March 2025.TG Therapeutics Management Team Effectiveness
At this time, TG Therapeutics' Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.04 in 2025, whereas Return On Capital Employed is likely to drop 0.07 in 2025. At this time, TG Therapeutics' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 383.9 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 7.6 M in 2025. TG Therapeutics' management efficiency ratios could be used to measure how well TG Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Common Stock Shares Outstanding is likely to rise to about 179.3 M in 2025, whereas Net Loss is likely to drop (172.6 M) in 2025.
TG Therapeutics Workforce Comparison
TG Therapeutics is rated fifth in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 3,071. TG Therapeutics retains roughly 319 in number of employees claiming about 10% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.05) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.15 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.15. TG Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific TG Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on TG Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, TG Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2025-03-01 | 1.0 | 2 | 2 | 837,500 | 21,358 |
| 2024-06-01 | 2.5 | 5 | 2 | 111,250 | 25,933 |
| 2024-03-01 | 0.5 | 2 | 4 | 1,076,908 | 92,367 |
| 2023-09-01 | 5.0 | 5 | 1 | 180,000 | 20,000 |
| 2023-03-01 | 3.0 | 3 | 1 | 1,079,000 | 30,000 |
| 2021-12-01 | 0.3333 | 1 | 3 | 56,394 | 712,000 |
| 2020-12-01 | 1.0 | 1 | 1 | 20,000 | 30,000 |
| 2020-09-01 | 2.0 | 2 | 1 | 250,000 | 158,589 |
| 2020-06-01 | 3.0 | 6 | 2 | 1,681,029 | 22,745 |
| 2019-09-01 | 5.0 | 5 | 1 | 135,240 | 17,654 |
| 2018-06-01 | 7.0 | 7 | 1 | 1,108,011 | 25,071 |
| 2017-06-01 | 1.4 | 7 | 5 | 924,877 | 425,524 |
| 2017-03-01 | 1.0 | 2 | 2 | 3,378,371 | 3,390,682 |
| 2016-09-01 | 3.0 | 6 | 2 | 74,754 | 379,190 |
| 2015-06-01 | 1.75 | 7 | 4 | 2,860,592 | 2,523,800 |
| 2015-03-01 | 0.5 | 1 | 2 | 114,855 | 66,401 |
| 2014-12-01 | 0.5 | 2 | 4 | 278,603 | 248,659 |
| 2013-12-01 | 3.0 | 3 | 1 | 576,920 | 23,106 |
| 2012-12-01 | 2.0 | 4 | 2 | 562,743 | 2,500,000 |
| 2012-06-01 | 3.0 | 9 | 3 | 5,726,060 | 426,914 |
| 2010-03-01 | 5.5 | 11 | 2 | 3,612,688 | 0.00 |
| 2008-03-01 | 1.4 | 7 | 5 | 2,775,000 | 78,571,429 |
| 2006-09-01 | 9.0 | 9 | 1 | 300,000 | 0.00 |
| 2006-03-01 | 5.0 | 5 | 1 | 395,520 | 0.00 |
| 2005-09-01 | 1.0 | 1 | 1 | 44,168 | 4,859 |
| 2005-06-01 | 34.0 | 34 | 1 | 7,401,098 | 0.00 |
| 2004-09-01 | 3.0 | 12 | 4 | 371,000 | 58,642 |
| 2004-03-01 | 10.0 | 10 | 1 | 1,872,888 | 200,000 |
| 2003-12-01 | 0.5 | 1 | 2 | 24,294 | 232,109 |
TG Therapeutics Notable Stakeholders
A TG Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as TG Therapeutics often face trade-offs trying to please all of them. TG Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting TG Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Sean CPA | Corporate CFO | Profile | |
| Jenna Bosco | Director of Investor Relations | Profile | |
| CPA CPA | Corp CFO | Profile | |
| Adam Waldman | Chief Commercial Officer | Profile | |
| Michael Esq | CEO Chairman | Profile |
About TG Therapeutics Management Performance
The success or failure of an entity such as TG Therapeutics often depends on how effective the management is. TG Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of TGTX management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the TGTX management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.03 | 0.04 | |
| Return On Capital Employed | 0.09 | 0.07 | |
| Return On Assets | 0.03 | 0.04 | |
| Return On Equity | 0.07 | 0.07 |
Please note, the imprecision that can be found in TG Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of TG Therapeutics. Check TG Therapeutics' Beneish M Score to see the likelihood of TG Therapeutics' management manipulating its earnings.
TG Therapeutics Workforce Analysis
Traditionally, organizations such as TG Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare TG Therapeutics within its industry.TG Therapeutics Manpower Efficiency
Return on TG Therapeutics Manpower
| Revenue Per Employee | 732.5K | |
| Revenue Per Executive | 46.7M | |
| Net Income Per Employee | 39.7K | |
| Net Income Per Executive | 2.5M | |
| Working Capital Per Employee | 828.3K | |
| Working Capital Per Executive | 52.8M |
Additional Tools for TGTX Stock Analysis
When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.